Atossa Therapeutics, Inc. (ATOS)

Last Closing Price: 1.81 (2026-11-18)

Company Description

Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company develops medicines in areas of significant unmet medical need in oncology principally in the United States. Its lead drug candidate is oral (Z)-endoxifen. Atossa Therapeutics Inc., formerly known as Atossa Genetics Inc., is based in Seattle, Washington.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-34.77M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.83
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -117.07%
Return on Assets (Trailing 12 Months) -96.08%
Current Ratio (Most Recent Fiscal Quarter) 5.35
Quick Ratio (Most Recent Fiscal Quarter) 5.35
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $2.18
Earnings per Share (Most Recent Fiscal Quarter) $-0.56
Earnings per Share (Most Recent Fiscal Year) $-4.04
Diluted Earnings per Share (Trailing 12 Months) --
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 9.98M
Free Float 9.00M
Market Capitalization $18.06M
Average Volume (Last 20 Days) 0.05M
Beta (Past 60 Months) 1.38
Percentage Held By Insiders (Latest Annual Proxy Report) 9.80%
Percentage Held By Institutions (Latest 13F Reports) 12.74%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%